Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
In all eukaryotes, the mechanistic target of rapamycin (mTOR) signaling emerges as a master regulator of homeostasis, which integrates environmental inputs, including nutrients, energy, and growth factors, to regulate many fundamental cellular processes such as cell growth and metabolism. mTOR signaling functions through two structurally and functionally distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), which correspond to two major branches of signal output. While mTORC1 is well characterized for its structure, regulation, and function in the last decade, information of mTORC2 signaling is only rapidly expanding in recent years, from structural biology, signaling network, to functional impact. Here we review the recent advances in many aspects of the mTORC2 signaling, with particular focus on its involvement in the control of cell metabolism and its physiological implications in metabolic diseases and aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982 · cited 1×
“Aging is a natural process, commonly accompanied by a progressive loss of physiological functions and increased susceptibility to age-associated diseases, including cardiovascular diseases, neurodegenerative diseases, infectious diseases, and cancers, thus ultimately limiting the health and lifespan [109].”
BackgroundmTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 3×
“In addition, Rapamycin derivatives have been applied to cancer treatment in clinical trials with limited efficiency, which is thought to be due to the limitation to inhibit mTORC2 [2].”
BackgroundInfluentialRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 2×
“Inhibition of mTOR by rapamycin showed 9–14% increase in the maximum lifespan of both male and female mice [115], indicating the importance of mTOR signaling in longevity.”
BackgroundAerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“As such, the second-generation ATPcompetitive inhibitors against mTOR kinase have entered clinical trials [105].”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · cited 1×
“T2DM is a metabolic disorder, characterized by dysregulation of carbohydrate, lipid, and protein metabolism as a result of impaired insulin secretion, insulin resistance, or both combined [94].”
BackgroundMechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · cited 1×
“Second, it also increases lipolysis, leading to increased circulating FFAs, which then accumulate in tissues and impair insulin signaling [100].”
BackgroundGao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487 · cited 1×
“The effect of mTORC2 on gluconeogenesis mainly results from the upregulation of several key gluconeogenic enzymes, such as G6Pase and PEPCK, through Akt-mediated FoxO1-phosphorylation, which leads to nuclear exclusion of FoxO1 and reduction of its transcriptional activities [67, 68].”
BackgroundRegulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients
Kaeberlein, M., Powers, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S., & Kennedy, B. K. (2005) · Science · doi:10.1126/science.1115535 · Cited by 1,293
mTOR kinase structure, mechanism and regulation
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075 · cited 2×
“However, its active site is usually recessed due to the FRB domain and an inhibitory helix protruding from the catalytic cleft, indicating that its accessibility is strictly regulated [6].”
BackgroundGarcía-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907 · cited 1×
“SGK1 is also phosphorylated and activated by mTORC2 at its S422 of HM, similar to that of Akt [29], 3 Oxidative Medicine and Cellular Longevity”
MethodFatty acids, obesity, and insulin resistance: Time for a reevaluation
Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011) · Diabetes · doi:10.2337/db11-0425 · Cited by 896 · cited 1×
“Although elevated FFA is not necessarily associated with insulin resistance [81], increasing adipose lipolysis could increase hepatic glucose production and cause insulin resistance [82].”
BackgroundmTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J. H., Asara, J. M., & Manning, B. D. (2016) · Science · doi:10.1126/science.aad0489 · Cited by 795
Perry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719 · cited 1×
“Although elevated FFA is not necessarily associated with insulin resistance [81], increasing adipose lipolysis could increase hepatic glucose production and cause insulin resistance [82].”
Background(Patho)physiological Significance of the Serum- and Glucocorticoid-Inducible Kinase Isoforms
Lang, F., Böhmer, C., Palmada, M., Seebohm, G., Strutz-Seebohm, N., & Vallon, V. (2006) · Physiological Reviews · doi:10.1152/physrev.00050.2005 · Cited by 689 · cited 1×
“mTORC2-targeted SGK1 activation functions to regulate sodium transport as well as cell survival [31].”
BackgroundBetz, C., Stracka, D., Prescianotto-Baschong, C., Frieden, M., Demaurex, N., & Hall, M. N. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302455110 · Cited by 538 · cited 2×
“mTORC2 is able to increase HK activity and glycolysis via Akt-dependent and -independent mechanisms [62].”
BackgroundAkt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator
Li, X., Monks, B., Ge, Q., & Birnbaum, M. J. (2007) · Nature · doi:10.1038/nature05861 · Cited by 487 · cited 1×
“In addition, mTORC2-mediated Akt activation is also responsible for the phosphorylation and inhibition of PGC1α (peroxisome proliferatoractivated receptor gamma coactivator 1-alpha), a transcription coactivator involved in activating gluconeogenic gene expression [69].”
BackgroundMasui, K., Tanaka, K., Akhavan, D., Babic, I., Gini, B., Matsutani, T., Iwanami, A., Liu, F., Villa, G. R., Gu, Y., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.013 · Cited by 407
Architecture of human mTOR complex 1
Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344 · cited 2×
“These differences are likely resulted from the distinct molecular compositions and have profound impact on the functions and regulations of the two complexes, rendering mTORC2 insensitive to rapamycin [11, 16].”
BackgroundRac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size
Saci, A., Cantley, L. C., & Carpenter, C. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.017 · Cited by 275
Rosario, F. J., Kanai, Y., Powell, T. L., & Jansson, T. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2012.238014 · Cited by 185 · cited 2×
“For example, mTORC2 regulates cell surface abundance of specific transporter isoforms SLC7A5 and SLC38A2 without affecting their global protein expression [84], and mTORC2 phosphorylates of serine 26 and inhibits cystine-glutamate antiporter xCT-mediated cystine uptake and glutathione synthesis [83].”
BackgroundSignaling networks determining life span
Riera, C. E., Merkwirth, C., De Magalhaes Filho, C. D., & Dillin, A. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014451 · Cited by 161 · cited 1×
“The velocity of aging is affected by a large number of environmental or genetic factors, such as nutrition sensing, DNA damage, stem cell maintenance, energy, and oxidative metabolism [110], and three sets of key proteins have been reported to modulate aging process: mTOR signaling, insulin/IGF (insulin-like growth fa…”
BackgroundMeng, Z.-X., Li, S., Wang, L., Ko, H. J., Lee, Y., Jung, D. Y., Okutsu, M., Yan, Z., Kim, J. K., & Lin, J. D. (2013) · Nature Medicine · doi:10.1038/nm.3144 · Cited by 146
Cited by
Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes
Takahara, T., Amemiya, Y., Sugiyama, R., Maki, M., & Shibata, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00679-2 · Cited by 300
“mTORC2 phosphorylates members of the AGC kinase family, such as Akt (also known as protein kinase B), the protein kinase C (PKC), and the serum/glucocorticoid regulated kinase 1 (SGK1), thereby regulating cell proliferation, survival, and actin cytoskeleton organization in response to growth factors [18, 30] (Fig.”
BackgroundThe Emerging Roles of mTORC1 in Macromanaging Autophagy
Dossou, A. S., & Basu, A. (2019) · Cancers · doi:10.3390/cancers11101422 · Cited by 288
mTOR signaling and Alzheimer's disease: What we know and where we are?
Davoody, S., Asgari Taei, A., Khodabakhsh, P., & Dargahi, L. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14463 · Cited by 96
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Metadata
- Authors
- Luo, Y., Xu, W., Li, G., & Cui, W.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 2018
- Issue
- 1
- Pages
- 7838647-7838647
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2899214804
- Cited by
- 75
- References
- 27
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.